Article

Control of Viremia and Prevention of AIDS following Immunotherapy of SIV-Infected Macaques with Peptide-Pulsed Blood

Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia.
PLoS Pathogens (Impact Factor: 8.06). 06/2008; 4(5):e1000055. DOI: 10.1371/journal.ppat.1000055
Source: PubMed

ABSTRACT Effective immunotherapies for HIV are needed. Drug therapies are life-long with significant toxicities. Dendritic-cell based immunotherapy approaches are promising but impractical for widespread use. A simple immunotherapy, reinfusing fresh autologous blood cells exposed to overlapping SIV peptides for 1 hour ex vivo, was assessed for the control of SIV(mac251) replication in 36 pigtail macaques. An initial set of four immunizations was administered under antiretroviral cover and a booster set of three immunizations administered 6 months later. Vaccinated animals were randomized to receive Gag peptides alone or peptides spanning all nine SIV proteins. High-level, SIV-specific CD4 and CD8 T-cell immunity was induced following immunization, both during antiretroviral cover and without. Virus levels were durably approximately 10-fold lower for 1 year in immunized animals compared to controls, and a significant delay in AIDS-related mortality resulted. Broader immunity resulted following immunizations with peptides spanning all nine SIV proteins, but the responses to Gag were weaker in comparison to animals only immunized with Gag. No difference in viral outcome occurred in animals immunized with all SIV proteins compared to animals immunized against Gag alone. Peptide-pulsed blood cells are an immunogenic and effective immunotherapy in SIV-infected macaques. Our results suggest Gag alone is an effective antigen for T-cell immunotherapy. Fresh blood cells pulsed with overlapping Gag peptides is proceeding into trials in HIV-infected humans.

Download full-text

Full-text

Available from: Kim Wilson, Aug 13, 2015
0 Followers
 · 
122 Views
  • Source
    • "Despite these efforts, standard vaccine delivery of peptides appears to have limited utility in stimulating CD8 T-cell responses, with the exception of one approach. Intravenous infusion of peripheral blood mononuclear cells coated ex vivo with peptides has shown great potency in preclinical animal studies (De Rose et al. 2008). Whether this approach will prove useful in human testing, especially considering the impracticality of such an approach for mass vaccination efforts, remains to be seen. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Vaccines are arguably the most powerful medical intervention in the fight against infectious diseases. The enormity of the global human immunodeficiency virus type 1 (HIV)/acquired immunodeficiency syndrome (AIDS) pandemic makes the development of an AIDS vaccine a scientific and humanitarian priority. Research on vaccines that induce T-cell immunity has dominated much of the recent development effort, mostly because of disappointing efforts to induce neutralizing antibodies through vaccination. Whereas T cells are known to limit HIV and other virus infections after infection, their role in protection against initial infection is much less clear. In this article, we will review the rationale behind a T-cell-based vaccine approach, provide an overview of the methods and platforms that are being applied, and discuss the impact of recent vaccine trial results on the future direction of T-cell vaccine research.
    Cold Spring Harbor Perspectives in Medicine 09/2011; 1(1):a007252. DOI:10.1101/cshperspect.a007252 · 7.56 Impact Factor
  • Source
    • "It was previously observed that vaccination during ART using DNA plasmids (Lisziewicz et al., 2005; Lori et al., 2005; Fuller et al., 2006; Lisziewicz et al., 2007; von Gegerfelt et al., 2007; Halwani et al., 2008; Zur Megede et al., 2008), pox-virus vectors (Hel et al., 2000; Tryniszewska et al., 2002), antigen-pulsed dendritic cells (Lu et al., 2003) or peptide-pulsed blood (De Rose et al., 2008) in SIVmac251-infected macaques was able to evoke SIV-specific recall immune responses. After release from ART, variable results regarding virological benefit were reported from no control (Zur Megede et al., 2008), temporal control (Hel et al., 2000; Tryniszewska et al., 2002; Fuller et al., 2006), to long-lasting control (Lori et al., 2003; Lu et al., 2003; Lisziewicz et al., 2005; von Gegerfelt et al., 2007; De Rose et al., 2008). Using DNA only as vaccine, two reports showed successful immunological and virological benefit, which are intramuscular injection (von Gegerfelt et al., 2007) and topical administration of DNAbased Dermavir (Lori et al., 2003; Lisziewicz et al., 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We have previously reported that therapeutic immunization by intramuscular injection of optimized plasmid DNAs encoding SIV antigens effectively induces immune responses able to reduce viremia in antiretroviral therapy (ART)-treated SIVmac251-infected Indian rhesus macaques. We subjected such therapeutically immunized macaques to a second round of therapeutic vaccination using a combination of plasmids expressing SIV genes and the IL-15/IL-15 receptor alpha as molecular adjuvant, which were delivered by the more efficacious in vivo constant-current electroporation. A very strong induction of antigen-specific responses to Gag, Env, Nef, and Pol, during ART (1.2-1.6% of SIV-specific T cells in the circulating T lymphocytes) was obtained with the improved vaccination method. Immunological responses were characterized by the production of IFN-gamma, IL-2, and TNF-alpha either alone, or in combination as double or triple cytokine positive multifunctional T cells. A significant induction of CD4(+) T cell responses, mainly targeting Gag, Nef, and Pol, as well as of CD8(+) T cells, mainly targeting Env, was found in both T cells with central memory and effector memory markers. After release from ART, the animals showed a virological benefit with a further approximately 1 log reduction in viremia. Vaccination with plasmid DNAs has several advantages over other vaccine modalities, including the possibility for repeated administration, and was shown to induce potent, efficacious, and long-lasting recall immune responses. Therefore, these data support the concept of adding DNA vaccination to the HAART regimen to boost the HIV-specific immune responses.
    Vaccine 02/2010; 28(8):1962-74. DOI:10.1016/j.vaccine.2009.10.099 · 3.49 Impact Factor
  • Source
    • "To identify individual Env epitopes we performed the IFNγ ICS assay progressively smaller peptide pools and then purchased minimal using peptide epitopes and performed titration series as shown in Fig. 1 (Peut and Kent, 2007). SIV viral load in plasma and CD4 T-cell depletion was monitored as previously described (De Rose et al., 2008). To analyze viral escape at Env CD8 T-cell epitopes, we cloned and sequenced plasma SIV RNA from animals responding at Env epitopes at multiple times during the course of infection as previously described (Peut and Kent, 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: It is unknown which HIV proteins to target by vaccination in order to generate the most effective CD8 T-cell immunity. We recently immunized SIV(mac251)-infected pigtail macaques with Gag peptides or a cocktail of peptides spanning all SIV proteins, including SIV Env. High-level SIV Env-specific CD8 T-cell responses were generated and 7 novel Env-specific CD8 T-cell epitopes in 10 animals were mapped. Env-specific CD8 T-cell responses were significantly inferior to Gag-specific responses, and no better than unvaccinated control animals, in the control of SIV replication and prevention of disease. Escape mutations emerged within several Env-specific CTL epitopes, suggesting at least some pressure imparted by the Env CTL responses, but this did not correlate with significantly reduced SIV replication. We conclude Env-specific CTL may not be the most effective response to induce by vaccination.
    Virology 02/2009; 384(1):21-7. DOI:10.1016/j.virol.2008.11.030 · 3.28 Impact Factor
Show more